opnMe News

Let´s live innovation. Want to know the latest news and trends? Read more

Subscribe to our newsletter to stay up to date with latest developments

Latest news

04 June 2018

As of today, Boehringer Ingelheim offers you another well-characterized and potent inhibitor via opnMe.com: BI-4659 inhibits Alk5 which is also known as TGFβR1. Therapeutic approaches to inhibit TGFβ receptor I (TGFβRI/Alk5) signaling have been discussed for the treatment of several diseases such as idiopathic pulmonary fibrosis and cancer.

17 May 2018

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel disease hypotheses for its Complex I ROS modulators.

08 May 2018

Have you ever wondered what the connection is between two search items? With our BI Miner co-occurrence function, you have now a tool at hand on opnMe.com to answer your questions. All for free – no costs associated. For example, if you are interested in the role of BCL6 in cancer, type “BCL6” and “Cancer” into the search fields and select your source.

26 April 2018

Are you ready to take the next step with BI Miner on opnMe.com? An innovative search function allows you to search for compounds based on chemical structure.

20 April 2018

We have now launched an updated and greatly expanded version of BI Miner on opnMe. Its mission is to save time and effort when performing online scientific queries as it combines several search modes into one single tool. The search engine works very intuitively and is pretty much self-explainable.

12 April 2018

Our β2 adrenergic receptor (β2AR ) agonist BI-167107 was used to support crystallization of active state β2AR and β2AR-G-protein complexes by Prof. Brian K. Kobilka as highlighted in his Nobel Prize Lecture in 2012 (The Structural Basis of G-Protein-Coupled Receptor Signaling (2012 Nobel Prize for Chemistry)). The compound could potentially be employed for the crystallization of other beta receptors.

19 March 2018

Boehringer Ingelheim’s well-characterized, potent and selective BRD9 inhibitor BI-9564 and the dual BRD7/BRD9 inhibitor BI-7273 are now available on opnMe.com. Both were developed in collaboration with the Structural Genomics Consortium (SGC).

21 February 2018

(“A problem shared”, Issue #218 / Feb 2018) features an interview with Adrian Carter, Corporate Vice President and Global Head Discovery Research Coordination, Boehringer Ingelheim. He talks about the strengths and merits of open innovation and crowdsourcing in the context of the pharmaceutical industry.

5 February 2018

We have released Boehringer Ingelheim’s well-characterized, potent and selective MMP-13 (Matrix metalloproteinase-13) inhibitor BI-4394 on opnMe.com.

18 January 2018

You will have free access to our unprecedented, potent and selective SGLT6 inhibitor in order to test your scientific hypotheses and identify novel diseases, indications or pathways linked to SGLT6.